Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

Peter J Simm; Jesper Johannesen; Julie Briody; Mary McQuade; Brian Hsu; Corinne Bridge; David G Little; Christopher T Cowell; Craig F Munns

doi:10.1016/j.bone.2011.07.031

Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

Peter J Simm, Jesper Johannesen, Julie Briody, Mary McQuade, Brian Hsu, Corinne Bridge, David G Little, Christopher T Cowell, Craig F Munns

38 Citations (Scopus)

Abstract

There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p

Original language	English
Journal	Bone
Volume	49
Issue number	5
Pages (from-to)	939-43
Number of pages	5
ISSN	8756-3282
DOIs	https://doi.org/10.1016/j.bone.2011.07.031
Publication status	Published - Nov 2011

Access to Document

10.1016/j.bone.2011.07.031

Cite this

@article{cb2351f84845460c8efd4ca11df8576f,

title = "Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis",

abstract = "There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p",

author = "Simm, {Peter J} and Jesper Johannesen and Julie Briody and Mary McQuade and Brian Hsu and Corinne Bridge and Little, {David G} and Cowell, {Christopher T} and Munns, {Craig F}",

year = "2011",

month = nov,

doi = "10.1016/j.bone.2011.07.031",

language = "English",

volume = "49",

pages = "939--43",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

AU - Simm, Peter J

AU - Johannesen, Jesper

AU - Briody, Julie

AU - McQuade, Mary

AU - Hsu, Brian

AU - Bridge, Corinne

AU - Little, David G

AU - Cowell, Christopher T

AU - Munns, Craig F

PY - 2011/11

Y1 - 2011/11

N2 - There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p

AB - There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD±1.24 over first 12 months, p

U2 - 10.1016/j.bone.2011.07.031

DO - 10.1016/j.bone.2011.07.031

M3 - Journal article

SN - 8756-3282

VL - 49

SP - 939

EP - 943

JO - Bone

JF - Bone

IS - 5

ER -

Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis

Abstract

Access to Document

Fingerprint

Cite this